Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
NCT03471286 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · PHASE1 · terminated · last registry update 2021-08-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Deprioritization of drug in this patient population” | – | Registry record, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IDO1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-03-08Also stopped (withdrawn): City of Hope Medical Center, Epacadostat + Pembrolizumab (NCT03592407)
- 2022-02-28Results posted on the registry: Bristol-Myers Squibb, BMS-986205 + Nivolumab (NCT03792750)
- 2022-02-28Results posted on the registry: Incyte Corporation, Epacadostat + Nivolumab (NCT03347123)
- 2022-02-28Also stopped (terminated): Incyte Corporation, Epacadostat + Nivolumab (NCT03347123)
- 2022-01-11Results posted on the registry: Merck Sharp & Dohme LLC, Epacadostat 25 mg + Epacadostat 100 mg (NCT02862457)
- 2021-12-21Results posted on the registry: University of California, Davis, epacadostat + SD-101 (NCT03322384)
- 2021-07-22Results posted on the registry: Incyte Biosciences International Sàrl, INCAGN01876 + Epacadostat (NCT03277352)
- 2021-07-22Also stopped (terminated): Incyte Biosciences International Sàrl, INCAGN01876 + Epacadostat (NCT03277352)
- 2021-07-09Results posted on the registry: Bristol-Myers Squibb, BMS-986205 + Nivolumab (NCT03329846)
- 2021-03-22Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Dasatinib (NCT02750514)
- 2021-03-22Also stopped (terminated): Bristol-Myers Squibb, Nivolumab + Dasatinib (NCT02750514)
- 2021-02-26Also stopped (withdrawn): Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Pembrolizumab + Epacadostat (NCT03832673)
- 2020-12-29Results posted on the registry: Incyte Corporation, MEDI4736 + INCB024360 (NCT02318277)
- 2020-10-26Also stopped (withdrawn): Alain Algazi, Durvalumab + Epacadostat (NCT04231864)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision